drugset / Trial / NCT05394168
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of HLX53 (an anti-TIGIT Fc fusion protein) in patients with advanced/metastatic solid tumors.
Timeline
- Start
- 2022-12-09
- Primary completion
- 2024-12-04
- Completion
- 2025-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX53 | Protein / enzyme biologic | 30 mg | Intravenous |
| Subject | HLX53 | Protein / enzyme biologic | 150 mg | Intravenous |
| Subject | HLX53 | Protein / enzyme biologic | 400 mg | Intravenous |
| Subject | HLX53 | Protein / enzyme biologic | 1000 mg | Intravenous |
| Subject | HLX53 | Protein / enzyme biologic | 2000 mg | Intravenous |
Indications
No indication recorded.